DGIdb - TOREMIFENE Drug Record

TOREMIFENE chembl:CHEMBL1655 ApprovedAntineoplastic

Alternate Names:

J33.157K
TOREMIFENE
GTX-006
TOREMIFENUM
TOREMIFENO
FARESTONE®
FC-1157A
chemidplus:89778-26-7
drugbank:00539
rxcui:38409
chembl:CHEMBL1655
pubchem.compound:3005573

Drug Info:

Year of Approval	1997
Drug Class	antineoplastic agents, hormonal
FDA Approval	not approved
Drug Indications	antineoplastic agent
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent,SERM

(3 More Sources)

Publications:

Ariazi et al., 2006, Estrogen receptors as therapeutic targets in breast cancer., Curr Top Med Chem
Jones et al., 2004, A review of adjuvant hormonal therapy in breast cancer., Endocr. Relat. Cancer
Locci et al., 2001, Synthesis and secretion of transforming growth factor-beta1 by human desmoid fibroblast cell line and its modulation by toremifene., J. Interferon Cytokine Res.
Shelly et al., 2008, Selective estrogen receptor modulators: an update on recent clinical findings., Obstet Gynecol Surv
Goldstein, 2006, Controversies in adjuvant endocrine treatment of premenopausal women., Clin. Breast Cancer
Lewis-Wambi et al., Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs)., Breast Dis
Taneja et al., 2006, Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy., Expert Opin Investig Drugs
Liu et al., 2003, Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites., Chem. Res. Toxicol.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Smith, 2006, Treatment-related osteoporosis in men with prostate cancer., Clin. Cancer Res.
Gennari et al., 2007, Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development., Drugs Aging
Hong et al., 2002, Antiproliferative properties of toremifene on AIDS-related Kaposi's sarcoma cells., Chemotherapy
Komi et al., 2000, Toremifene increases the expression of intercellular adhesion molecule-1 (ICAM-1) on MCF-7 breast cancer cells and Jurkat cells., Scand. J. Immunol.
Pyykkö et al., 1994, Aryl hydrocarbon hydroxylase activity in chemically induced and toremifene-treated mammary tumors in rats., Int. J. Cancer
Kivistö et al., 1998, Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin., Clin. Pharmacol. Ther.
Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
Valavaara et al., 1990, Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene., Cancer

TOREMIFENE CD80

Interaction Score: 2.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10632979

Sources:
NCI
TOREMIFENE ESR1

Interaction Score: 0.73

Interaction Types & Directionality:

modulator

Interaction Info:

Trial Name Acapodene

Novel drug target Established target

Trial Name atamestane-plus-toremifene

PMIDs:
16515478 15369444 11747628 18279543 16595024 16917142 16503765 12870885 11752352 17062721 17503894

Sources:
TdgClinicalTrial TEND PharmGKB TTD FDA
TOREMIFENE CYP1B1

Interaction Score: 0.63

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8262671

Sources:
NCI
TOREMIFENE TGFB1

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12476040

Sources:
NCI
TOREMIFENE PGR

Interaction Score: 0.35

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2147123

Sources:
NCI
TOREMIFENE ESR2

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name atamestane-plus-toremifene

PMIDs:
None found

Sources:
TdgClinicalTrial PharmGKB
TOREMIFENE CYP3A4

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9871429 9187528

Sources:
NCI PharmGKB

TEND: TOREMIFENE
- Version: 01-August-2011
Alternate Names:

TOREMIFENE Primary Drug Name

Drug Info:

Drug Class antineoplastic agents, hormonal

Year of Approval 1997

Publications:
TdgClinicalTrial: TOREMIFENE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent,SERM

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: TOREMIFENE

Version: 14-September-2017

Alternate Names:

C1256 NCI drug code

Drug Info:

Publications:

Hong et al., 2002, Antiproliferative properties of toremifene on AIDS-related Kaposi's sarcoma cells., Chemotherapy

Komi et al., 2000, Toremifene increases the expression of intercellular adhesion molecule-1 (ICAM-1) on MCF-7 breast cancer cells and Jurkat cells., Scand. J. Immunol.

Kivistö et al., 1998, Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin., Clin. Pharmacol. Ther.

PharmGKB: toremifene
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
TTD: Toremifene
- Version: 2020.06.01
Alternate Names:

D04VFJ TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1655
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Toremifene
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Trial Name	Acapodene
Novel drug target	Established target
Trial Name	atamestane-plus-toremifene

TOREMIFENE Drug Record

TOREMIFENE chembl:CHEMBL1655 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

TOREMIFENE CD80

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10632979

Sources: NCI

TOREMIFENE ESR1

Interaction Types & Directionality: modulator

Interaction Info: Trial Name Acapodene Novel drug target Established target Trial Name atamestane-plus-toremifene

PMIDs: 16515478 15369444 11747628 18279543 16595024 16917142 16503765 12870885 11752352 17062721 17503894

Sources: TdgClinicalTrial TEND PharmGKB TTD FDA

TOREMIFENE CYP1B1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8262671

Sources: NCI

TOREMIFENE TGFB1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12476040

Sources: NCI

TOREMIFENE PGR

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 2147123

Sources: NCI

TOREMIFENE ESR2

Interaction Types & Directionality: n/a

Interaction Info: Novel drug target Established target Trial Name atamestane-plus-toremifene

PMIDs: None found

Sources: TdgClinicalTrial PharmGKB

TOREMIFENE CYP3A4

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9871429 9187528

Sources: NCI PharmGKB

TEND: TOREMIFENE

Alternate Names: TOREMIFENE Primary Drug Name

Drug Info: Drug Class antineoplastic agents, hormonal Year of Approval 1997

Publications:

TdgClinicalTrial: TOREMIFENE

Alternate Names:

Drug Info: Drug Indications antineoplastic agent,SERM Drug Class Small Molecule FDA Approval approved

Publications:

NCI: TOREMIFENE

Alternate Names: C1256 NCI drug code

Drug Info:

PharmGKB: toremifene

Alternate Names:

Drug Info:

Publications: Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev

TTD: Toremifene

Alternate Names: D04VFJ TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1655

Alternate Names:

Drug Info:

Publications:

FDA: Toremifene

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
10632979

Sources:
NCI

Interaction Types & Directionality:

modulator

Interaction Info:

Trial Name Acapodene

Novel drug target Established target

Trial Name atamestane-plus-toremifene

PMIDs:
16515478 15369444 11747628 18279543 16595024 16917142 16503765 12870885 11752352 17062721 17503894

Sources:
TdgClinicalTrial TEND PharmGKB TTD FDA

Interaction Types & Directionality:

n/a

PMIDs:
8262671

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12476040

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
2147123

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name atamestane-plus-toremifene

PMIDs:
None found

Sources:
TdgClinicalTrial PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
9871429 9187528

Sources:
NCI PharmGKB

Alternate Names:

TOREMIFENE Primary Drug Name

Drug Info:

Drug Class antineoplastic agents, hormonal

Year of Approval 1997

Drug Info:

Drug Indications antineoplastic agent,SERM

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

C1256 NCI drug code

Publications:

Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev

Alternate Names:

D04VFJ TTD Drug ID